Diagnostic Performance of ASL-MRI and FDG-PET in Frontotemporal Dementia: A Systematic Review and Meta-Analysis

References

1. 1.↵
   1. Mulkey M

   . Understanding frontotemporal disease progression and management strategies. Nurs Clin North Am 2019;54:437–48 doi:10.1016/j.cnur.2019.04.011 pmid:31331629

   CrossRefPubMed
2. 2.↵
   1. Kurz A,
   2. Kurz C,
   3. Ellis K, et al

   . What is frontotemporal dementia? Maturitas 2014;79:216–19 doi:10.1016/j.maturitas.2014.07.001 pmid:25059437

   CrossRefPubMed
3. 3.↵
   1. Weder ND,
   2. Aziz R,
   3. Wilkins K, et al

   . Frontotemporal dementias: a review. Ann Gen Psychiatry 2007;6:15 doi:10.1186/1744-859X-6-15

   CrossRefPubMed
4. 4.↵
   1. Ratnavalli E,
   2. Brayne C,
   3. Dawson K, et al

   . The prevalence of frontotemporal dementia. Neurology 2002;58:1615–21 doi:10.1212/wnl.58.11.1615 pmid:12058088

   CrossRefPubMed
5. 5.↵
   1. Snowden JS,
   2. Bathgate D,
   3. Varma A, et al

   . Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 2001;70:323–32 doi:10.1136/jnnp.70.3.323 pmid:11181853

   Abstract/FREE Full Text
6. 6.↵
   1. Hodges JR,
   2. Davies R,
   3. Xuereb J, et al

   . Survival in frontotemporal dementia. Neurology 2003;61:349–54 doi:10.1212/01.wnl.0000078928.20107.52 pmid:12913196

   Abstract/FREE Full Text
7. 7.↵
   1. Khan I,
   2. De Jesus O

   . Frontotemporal lobe dementia. In: StatPearls; Treasure Island (FL): StatPearls Publishing; 2024
8. 8.↵
   1. Bott NT,
   2. Radke A,
   3. Stephens ML, et al

   . Frontotemporal dementia: diagnosis, deficits and management. Neurodegener Dis Manag 2014;4:439–54 doi:10.2217/nmt.14.34 pmid:25531687

   CrossRefPubMed
9. 9.↵
   1. Bang J,
   2. Spina S,
   3. Miller BL

   . Non-Alzheimer’s dementia 1. Lancet 2015;386:1672–82.

   CrossRefPubMed
10. 10.↵
    1. Diehl-Schmid J,
    2. Grimmer T,
    3. Drzezga A, et al

    . Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging 2007;28:42–50 doi:10.1016/j.neurobiolaging.2005.11.002 pmid:16448722

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Dukart J,
    2. Mueller K,
    3. Horstmann A, et al

    . Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One 2011;6:e18111 doi:10.1371/journal.pone.0018111 pmid:21448435

    CrossRefPubMed
12. 12.↵
    1. Foster NL,
    2. Heidebrink JL,
    3. Clark CM, et al

    . FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain 2007;130:2616–35 doi:10.1093/brain/awm177 pmid:17704526

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Kato T,
    2. Inui Y,
    3. Nakamura A, et al

    . Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev 2016;30:73–84 doi:10.1016/j.arr.2016.02.003 pmid:26876244

    CrossRefPubMed
14. 14.↵
    1. Ceccarini J,
    2. Bourgeois S,
    3. Van Weehaeghe D, et al

    . Direct prospective comparison of 18F-FDG PET and arterial spin labelling MR using simultaneous PET/MR in patients referred for diagnosis of dementia. Eur J Nucl Med Mol Imaging 2020;47:2142–54 doi:10.1007/s00259-020-04694-1 pmid:31960098

    CrossRefPubMed
15. 15.↵
    1. Verclytte S,
    2. Lopes R,
    3. Lenfant P, et al

    . Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early-onset Alzheimer’s disease. J Neuroimaging 2016;26:207–12 doi:10.1111/jon.12264 pmid:26031943

    CrossRefPubMed
16. 16.↵
    1. Daulatzai MA

    . Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. J Neurosci Res 2017;95:943–72 doi:10.1002/jnr.23777 pmid:27350397

    CrossRefPubMed
17. 17.↵
    1. Anazodo UC,
    2. Finger E,
    3. Kwan BYM, et al

    . Using simultaneous PET/MRI to compare the accuracy of diagnosing frontotemporal dementia by arterial spin labelling MRI and FDG-PET. Neuroimage Clin 2018;17:405–14 doi:10.1016/j.nicl.2017.10.033 pmid:29159053

    CrossRefPubMed
18. 18.↵
    1. Du AT,
    2. Jahng GH,
    3. Hayasaka S, et al

    . Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006;67:1215–20 doi:10.1212/01.wnl.0000238163.71349.78 pmid:17030755

    Abstract/FREE Full Text
19. 19.↵
    1. Fällmar D,
    2. Lilja J,
    3. Velickaite V, et al

    . Visual assessment of brain perfusion MRI scans in dementia: a pilot study. J Neuroimaging 2016;26:324–30 doi:10.1111/jon.12296 pmid:26376736

    CrossRefPubMed
20. 20.↵
    1. Fällmar D,
    2. Haller S,
    3. Lilja J, et al

    . Arterial spin labeling-based z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. Eur Radiology 2017;27:4237–46 doi:10.1007/s00330-017-4784-1 pmid:28374078

    CrossRefPubMed
21. 21.↵
    1. Tosun D,
    2. Schuff N,
    3. Rabinovici GD, et al

    . Diagnostic utility of ASL‐MRI and FDG‐PET in the behavioral variant of FTD and AD. Ann Clin Transl Neurol 2016;3:740–51 doi:10.1002/acn3.330 pmid:27752510

    CrossRefPubMed
22. 22.↵
    1. Verfaillie SCJ,
    2. Adriaanse SM,
    3. Binnewijzend MAA, et al

    . Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? Eur Radiology 2015;25:3050–59 doi:10.1007/s00330-015-3696-1 pmid:25899416

    CrossRefPubMed
23. 23.↵
    1. Weyts K,
    2. Vernooij M,
    3. Steketee R, et al

    . Qualitative agreement and diagnostic performance of arterial spin labelling MRI and FDG PET-CT in suspected early-stage dementia: comparison of arterial spin labelling MRI and FDG PET-CT in suspected dementia. Clin Imaging 2017;45:1–7 doi:10.1016/j.clinimag.2017.05.008 pmid:28551486

    CrossRefPubMed
24. 24.↵
    1. Kapasouri EM,
    2. Ioannidis DC,
    3. Cameron D, et al

    . The utility of arterial spin labeling MRI in medial temporal lobe as a vascular biomarker in Alzheimer’s disease spectrum: a systematic review and meta-analysis. Diagnostics (Basel) 2022;12:2967 doi:10.3390/diagnostics12122967

    CrossRefPubMed
25. 25.↵
    1. Haidar H,
    2. Majzoub RE,
    3. Hajeer S, et al

    . Arterial spin labeling (ASL-MRI) versus fluorodeoxyglucose-PET (FDG-PET) in diagnosing dementia: a systematic review and meta-analysis. BMC Neurol 2023;23:385doi:10.1186/s12883-023-03432-y

    CrossRefPubMed
26. 26.↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM, et al

    . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71 doi:10.1136/bmj.n71 pmid:33782057

    FREE Full Text
27. 27.↵
    1. Ouzzani M,
    2. Hammady H,
    3. Fedorowicz Z, et al

    . Rayyan–a Web and mobile app for systemic reviews. Syst Rev 2016;5:210 doi:10.1186/s13643-016-0384-4

    CrossRefPubMed
28. 28.↵
    1. Whiting PF,
    2. Rutjes AWS,
    3. Westwood ME

    ; QUADAS-2 Group, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36 doi:10.7326/0003-4819-155-8-201110180-00009 pmid:22007046

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Clopper CJ,
    2. Pearson ES

    . The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404–13 doi:10.1093/biomet/26.4.404

    CrossRef
30. 30.↵
    1. Nyaga VN,
    2. Arbyn M

    . Metadta: a STATA command for meta-analysis and meta-regression of diagnostic test accuracy data – a tutorial. Arch Public Health 2022;80:95 doi:10.1186/s13690-021-00747-5

    CrossRefPubMed
31. 31.↵
    1. Higgins JPT,
    2. Thompson SG,
    3. Deeks JJ, et al

    . Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60 doi:10.1136/bmj.327.7414.557 pmid:12958120

    FREE Full Text
32. 32.↵
    1. Shim SR,
    2. Kim S-J,
    3. Lee J

    . Diagnostic test accuracy: application and practice using r software. Epidemiol Health 2019;41:e2019007 doi:10.4178/epih.e2019007 pmid:30999739

    CrossRefPubMed
33. 33.↵
    1. Dolui S,
    2. Li Z,
    3. Nasrallah IM, et al

    . Arterial spin labeling versus 18F-FDG-PET to identify mild cognitive impairment. Neuroimage Clin 2020;25:102146 doi:10.1016/j.nicl.2019.102146 pmid:31931403

    CrossRefPubMed
34. 34.↵
    1. Jaganmohan D,
    2. Pan S,
    3. Kesavadas C, et al

    . A pictorial review of brain arterial spin labelling artefacts and their potential remedies in clinical studies. Neuroradiol J 2021;34:154–68 doi:10.1177/1971400920977031 pmid:33283653

    CrossRefPubMed
35. 35.↵
    1. Fan AP,
    2. Guo J,
    3. Khalighi MM, et al

    . Long-delay arterial spin labeling provides more accurate cerebral blood flow measurements in moyamoya patients: a simultaneous positron emission tomography/MRI study. Stroke 2017;48:2441–49 doi:10.1161/STROKEAHA.117.017773 pmid:28765286

    Abstract/FREE Full Text
36. 36.↵
    1. Gai ND,
    2. Butman JA

    . Determining the optimal postlabeling delay for arterial spin labeling using subject-specific estimates of blood velocity in the carotid artery. J Magn Reson Imaging 2019;50:951–60 doi:10.1002/jmri.26670 pmid:30681220

    CrossRefPubMed
37. 37.↵
    1. Mosconi L

    . Glucose metabolism in normal aging and Alzheimer’s disease: methodological and physiological considerations for PET studies. Clin Transl Imaging 2013;1:217–33 doi:10.1007/s40336-013-0026-y

    CrossRef
38. 38.↵
    1. Borogovac A,
    2. Asllani I

    . Arterial spin labeling (ASL) fMRI: advantages, theoretical constrains, and experimental challenges in neurosciences. Int J Biomed Imaging 2012;2012:818456 doi:10.1155/2012/818456 pmid:22966219

    CrossRefPubMed
39. 39.↵
    1. Mutsaerts HJ,
    2. Steketee RM,
    3. Heijtel DF, et al

    . Inter-vendor reproducibility of pseudo-continuous arterial spin labeling at 3 Tesla. PLoS One 2014;9:e104108 doi:10.1371/journal.pone.0104108 pmid:25090654

    CrossRefPubMed
40. 40.↵
    1. Dominguez Perez S,
    2. Phillips JS,
    3. Norise C, et al

    . Neuropsychological and neuroanatomical features of patients with behavioral/dysexecutive variant Alzheimer’s disease (AD): a comparison to behavioral variant frontotemporal dementia and amnestic AD groups. J Alzheimers Dis 2022;89:641–58 doi:10.3233/JAD-215728 pmid:35938245

    CrossRefPubMed